Stay updated on Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial
Sign up to get notified when there's something new on the Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial page.

Latest updates to the Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe ClinicalTrials.gov footer revision label changes from v3.7.2 to v3.8.0.SummaryDifference0.1%

- Check20 days agoChange DetectedA banner announces updates to NIH websites and explains that agencies are transitioning from the term “Artificial Intelligence” to “Super Intelligence.”SummaryDifference0.9%

- Check27 days agoChange DetectedThe website footer revision changes from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check34 days agoChange DetectedThe ClinicalTrials.gov page footer updates its site revision from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check55 days agoChange DetectedA minor UI text update for the contact information link and a new revision badge (v3.7.0) replacing the previous badge (v3.6.6) appear in the study record history, indicating a small interface change and a platform version update.SummaryDifference0.3%

- Check76 days agoChange DetectedThe Study Record History now lists revision v3.6.6, with v3.6.5 removed from the history. This indicates an update to the page's revision history and versioning metadata.SummaryDifference0.1%

Stay in the know with updates to Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial page.